eli lilly retatrutide trials VisualAbstract: reduces body weight by 17.5% in patients with obesity Lilly's triple agonist, retatrutide, delivered

Fournel, A

If you are taking a GLP-1 and experiencing symptoms like fatigue, low appetite, muscle loss concerns, brain fog, or difficulty meeting your nutritional needs, targeted lab testing can help evaluate blood sugar, insulin, and common nutrient deficiencies to guide your next steps

This production of ATP and modulation of the cellular ATP/ADP ratio may lead to continued closure of K + ATP channels and further depolarization

These factors support GLP-1 use in diabetes and obesity treatment

Dietrich Hauffe, Ph.D

The FRAX tool (Fracture Risk Assessment Tool) is a supplementary resource that estimates a patient's 10-year probability of hip fracture or major osteoporotic fracture based on clinical risk factors